Injection vehicle for polymer-based formulations
First Claim
1. A method for administering a biologically active agent, the method comprising:
- injecting to an animal a formulation comprising;
(a) an injection vehicle comprising hyaluronic acid or sodium hyaluronate dissolved in a physiological buffer at a concentration of about 0.01 to about 3 percent weight per volume; and
(b) particles comprising;
(i) a first component that is the biologically active agent; and
(ii) a second component that is a biocompatible polymeric matrix,wherein the concentration of the particles is about 100 mg/mL to about 500 mg/mL of the formulation, and further wherein the hyaluronic acid or sodium hyaluronate is at a concentration sufficient to inject the formulation through a 23-gauge or smaller bore needle.
1 Assignment
0 Petitions
Accused Products
Abstract
The invention provides injection vehicles suitable for administering particulate suspensions, such as polymer-based formulations, as well as associated pharmaceutical formulations, articles of manufacture, and kits. Other aspects of the invention included methods for producing and administering pharmaceutical formulations. The injection vehicles of the invention are superior to conventional injection vehicles in that they include a pseudoplastic composition that improves injectability, which facilitates delivery of the desired dose. The injection vehicles of the invention also allow the use of smaller-bore needles than are usually necessary to inject polymer-based formulations, reducing the pain associated with injection of such formulations.
-
Citations
44 Claims
-
1. A method for administering a biologically active agent, the method comprising:
-
injecting to an animal a formulation comprising; (a) an injection vehicle comprising hyaluronic acid or sodium hyaluronate dissolved in a physiological buffer at a concentration of about 0.01 to about 3 percent weight per volume; and (b) particles comprising; (i) a first component that is the biologically active agent; and (ii) a second component that is a biocompatible polymeric matrix, wherein the concentration of the particles is about 100 mg/mL to about 500 mg/mL of the formulation, and further wherein the hyaluronic acid or sodium hyaluronate is at a concentration sufficient to inject the formulation through a 23-gauge or smaller bore needle. - View Dependent Claims (2, 3, 4, 5, 6, 7, 8, 9, 10)
-
-
11. An injectable formulation, comprising:
-
(a) an injection vehicle comprising hyaluronic acid or sodium hyaluronate dissolved in a physiological buffer at a concentration of about 0.01 to about 3 percent weight by volume; and (b) particles, comprising; (i) a first component that is a biologically active agent, and (ii) a second component that is a biocompatible polymeric matrix, wherein the concentration of the particles is about 100 mg/mL to about 500 mg/mL of the formulation, and further wherein the hyaluronic acid or sodium hyaluronate is at a concentration sufficient to inject the particles through a 23-gauge or smaller bore needle. - View Dependent Claims (12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22, 23, 24, 25, 26, 27, 28, 29, 30, 31, 32, 33, 34, 35, 36, 37, 38, 39, 40, 41, 42, 43)
-
-
44. A method for making a pharmaceutical formulation, comprising:
-
adding an effective amount of a biologically active agent coated on, dispersed within, or coated on and dispersed within polymeric particles to an aqueous injection vehicle comprising hyaluronic acid or sodium hyaluronate at a concentration of about 0.01 to about 3% (w/v); wherein the concentration of particles in the formulation is between about 100 and 500 mg/mL (w/v); and
further wherein the hyaluronic acid or sodium hyaluronate is at a concentration sufficient to inject the particles through a 23-gauge or smaller bore needle.
-
Specification